Home TestMll T 4 11 Q21 Q23 Qualitative Test

MLL t(4;11)(q21;q23) Qualitative Test: Booking, Price, and Results

About MLL t(4;11)(q21;q23) Qualitative Test: Booking, Price, and Results

Field	Value
Also Known As	MLL-AF4 t(4;11) PCR, KMT2A-AFF1 translocation test, 11q23 translocation test, MLL rearrangement test, MLL gene fusion test.
Sample Type	Whole blood/bone marrow
Fasting Required	No fasting required
Report Time	15 days
Recommended For	Infants, children, and adults with suspected or confirmed acute leukaemia
Price	Starting at ₹6,000

What Is a MLL t(4;11)(q21;q23) Qualitative Test?

The MLL t(4;11)(q21;q23) qualitative test detects a specific chromosomal abnormality associated with certain types of acute leukaemia. The test identifies an abnormal fusion between the MLL gene (KMT2A) on chromosome 11 and the AF4 gene (AFF1) on chromosome 4. This gene fusion is commonly linked to aggressive forms of acute lymphoblastic leukaemia (ALL) and helps support diagnosis, risk assessment, and treatment planning. Also known as MLL gene fusion test or KMT2A-AFF1 translocation test. Doctors may recommend this test to help diagnose specific types of acute leukaemia, identify high-risk disease, guide treatment decisions, monitor disease status, or evaluate patients with suspected MLL/KMT2A gene rearrangements.

What Does a MLL t(4;11)(q21;q23) Qualitative Test Measure?

This test analyses the genetic material in your blood or bone marrow to check for one specific chromosomal abnormality. Here is what the test looks for:

Component	What It Detects
MLL-AF4 Fusion Gene Transcript	Presence or absence of the t(4;11) chromosomal translocation, where two genes fuse abnormally
Qualitative Result	Reports the finding as either "Detected" (positive) or "Not Detected" (negative)

The MLL t(4;11)(q21;q23) qualitative test uses next generation sequencing (NGS) to identify whether this specific gene rearrangement is present in the sample.

Why Is a MLL t(4;11)(q21;q23) Qualitative Test Done?

Doctors order this test when a patient shows signs that may point to a specific type of leukaemia, or when further genetic confirmation is needed after an initial diagnosis.

Common Symptoms That May Require This Test

A doctor may recommend this test when a patient presents with the following symptoms:

Persistent tiredness or fatigue without a clear cause.
Frequent infections that do not resolve easily.
Unexplained fever or high temperature.
Easy or unusual bruising
Swollen lymph nodes (glands in the neck, armpits, or groin).
Pain in bones or joints
Pale skin

Conditions This Test Can Help Detect

This test can help identify or confirm the following conditions:

B-cell acute lymphoblastic leukaemia (ALL), where the t(4;11) translocation is found in approximately 10% of newly diagnosed adult cases.
Infant ALL, where this translocation is present in more than 80% of cases and is the most common MLL rearrangement seen.
Acute myeloid leukaemia (AML) subtypes, including M4 and M5 types, in rare cases.
Secondary or treatment-related leukaemia, particularly following treatment with topoisomerase inhibitors.

MLL t(4;11)(q21;q23) Qualitative Test for Chronic Disease Monitoring

This test plays an important role in monitoring patients after treatment. Because the MLL-AF4 fusion sequence is unique to leukaemic cells, it can be used as a reliable marker to track minimal residual disease (MRD), which refers to small numbers of cancer cells that may remain after treatment. Repeat testing helps doctors assess how well treatment is working and detect any signs of disease coming back.

How to Prepare and What to Expect

No special preparation is needed before this test. However, there are a few practical points to keep in mind before your appointment.

Do You Need to Fast?

No, fasting is not required for the test. You may eat and drink normally before your sample is collected.

Practical Tips Before Your Test

Here are a few steps to help ensure a smooth and accurate sample collection:

Bring a detailed clinical history, including your symptoms, previous test results, and family history, as this is required for the test.
Carry a valid doctor's prescription, which is mandatory for this test.
Inform your doctor about all current medications, including any chemotherapy drugs you may be taking.
Ensure the sample reaches the laboratory as quickly as possible after collection, as prompt transport is essential for accurate results.

Step-by-Step Procedure

This test may require a bone marrow sample, a blood sample, or both. Here is what to expect during each collection.

Bone Marrow Sample Collection:

A doctor or specialist will clean the skin over the hip bone and apply a local anaesthetic to numb the area, minimising discomfort.
A thin needle is carefully inserted to draw a small amount of bone marrow aspirate, usually from the posterior iliac crest (back of the hip bone).
The sample is placed into a sterile EDTA (lavender-top) tube and gently inverted to prevent clotting.
You may feel some pressure or brief discomfort during aspiration; mild soreness at the site is normal for a day or two afterwards.
The labelled sample is sealed and prepared for immediate transport to the laboratory under refrigerated conditions (2 to 8 degrees Celsius).
The sample is dispatched to the laboratory promptly, as rapid transportation is essential for result accuracy.

Whole Blood Sample Collection:

A trained phlebotomist cleans the skin on the inside of your elbow.
A small blood sample of 3 ml is drawn into an EDTA (lavender-top) tube.
The tube is inverted gently, labelled, and prepared for transport under refrigerated conditions.
The sample is sent to the laboratory immediately for NGS-based analysis.

Factors That Can Affect Accuracy

The following factors can influence the reliability of your test results:

Poor quality or degraded RNA in the sample, which can affect the molecular analysis.
Delay in transporting the sample to the laboratory.
Insufficient leukaemic cells in the blood sample, making bone marrow the preferred option in some cases.
Incorrect anticoagulation or improper sample handling.
MLL rearrangements occurring in minor or atypical breakpoint regions, which may not be detected by standard testing methods.

Understanding Your MLL t(4;11)(q21;q23) Qualitative Test Results

Results from this test are reported as either "Detected" or "Not Detected." Your doctor will review these findings alongside your symptoms, medical history, and other test results to form a complete picture.

Parameter	Result	Interpretation
MLL-AF4 t(4;11)(q21;q23) Fusion Transcript	Not Detected (Negative)	No translocation found; this specific gene fusion is absent.
MLL-AF4 t(4;11)(q21;q23) Fusion Transcript	Detected (Positive)	The chromosomal translocation is present, indicating a specific high-risk leukaemia subtype.

These ranges are general guidelines. Your doctor will interpret your results based on your age, health history, and other factors. Always consult a qualified healthcare professional for personalised medical advice.

Results During Special Conditions

Certain situations can affect how results are interpreted:

Standard RT-PCR kits target the major breakpoint cluster region. If the MLL rearrangement occurs in a less common breakpoint region, or through an atypical mechanism such as a three-way translocation, the test may return a negative result even when an MLL rearrangement is present. Your doctor may request additional testing if clinical suspicion remains high.
Molecular testing for the MLL-AF4 fusion can sometimes identify the rearrangement even when it is not visible on standard chromosomal analysis, meaning this test may detect cases that conventional cytogenetics may miss.

How to Support Health During Treatment

Since this test detects a chromosomal abnormality associated with blood cancer, lifestyle changes cannot alter the genetic finding itself. However, the following measures may help support overall health and treatment monitoring:

Attend all follow-up appointments and repeat testing as advised by your haematologist or oncologist.
Inform your doctor promptly about any new or worsening symptoms.
Maintain overall health with adequate nutrition, hydration, rest, and supportive medical care during treatment and recovery.

Lupin Diagnostics MLL t(4;11)(q21;q23) Qualitative Test Price

The test is priced starting at ₹6,000 at Lupin Diagnostics. As this test requires specialised sample collection (bone marrow aspiration or blood draw by a trained professional), it must be done at a Lupin Diagnostics centre. Home collection is not available for this test.

City	Approximate Price (₹)
BHOPAL	6000
CHENNAI	6000
HYDERABAD	6000
KOLKATA	6000
NAVI MUMBAI	6000
PUNE	6000

Prices are indicative and may vary by location. Please confirm the current price at the time of booking.

How to Book

Follow these steps to book your test:

Select the test on the Lupin Diagnostics website.
Choose your city and preferred centre location.
Visit the centre at your scheduled time for sample collection by a trained specialist.
Receive your report via email or WhatsApp within the stipulated turnaround time.

Frequently Asked Questions

The MLL t(4;11)(q21;q23) qualitative test detects a specific gene fusion associated with a subtype of acute leukaemia. It is used to confirm a leukaemia diagnosis, assess disease risk, and guide treatment decisions. This translocation is seen in a proportion of adult B-cell acute lymphoblastic leukaemia (ALL) cases and is particularly common in infant ALL.

This test may be recommended for infants, children, and adults with suspected or confirmed acute leukaemia. It is especially important in infant ALL and in patients with high-risk B-cell ALL features.

Some discomfort is expected during bone marrow aspiration. Local anaesthesia is applied beforehand to reduce pain at the collection site. Mild soreness may persist for a day or two after the procedure, which is normal and usually settles on its own.

The presence of the t(4;11)(q21;q23) translocation is associated with a high-risk form of acute leukaemia. Early identification helps doctors plan appropriate treatment strategies and monitor the disease more effectively.

Yes, a peripheral blood sample can be used if leukaemic cells have entered the bloodstream. However, bone marrow is the preferred sample because it provides a more reliable and concentrated source of leukaemic cells. Your doctor will decide which sample type is most appropriate.

A positive result means the MLL-AF4 gene fusion was detected in the sample. This finding supports the diagnosis of a specific subtype of acute leukaemia and helps guide further treatment planning with a haematologist or oncologist.